DOCSLIB.ORG

Summit Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summit Program MARIJUANA BANKING SUMMIT J UNE 6, 2019 R ivers Casino | Pittsburgh, Pennsylvania It’s time we talk. It’s time we come together to tackle the issues head-on. Hosted by Integrated Compliance Solutions, LLC and Sterling Compliance, LLC SUMMIT AGENDA Opening Remarks Ralf Kaiser How Did We Get Here? Taylor Biehl The U.S. Cannabis Industry from Illegal to Legal Marijuana 101: You Don't Know What You Don't Know Michael Patterson Addressing the Cannabis Dichotomy for U.S. Financial Institutions Angela Lucas MRB Banking Needs, Challenges & Opportunities Ralf Kaiser Establishing the MRB Component of Your BSA | AML Program Angela Lucas Joseph Kopko MRB Insurance Programs Designed Evan Muffly to Manage Risks for Financial Institutions How to Automate and Scale Your Compliance Strategy Christopher Johnson Marijuana Banking Panel Michael Patterson Angela Lucas Christopher Johnson Evan Muffly Ken LaRoe Cannabis Banking: It CAN Be Done! Francis Grady ABOUT THE SPEAKERS Ken LaRoe Ken LaRoe has been dedicated to the economic well-being of Central Florida for more than 30 years. Mr. LaRoe has lent his expertise to several area businesses, and has created numerous banking jobs, supported various non-profit organizations across the region, and helped to grow well-established Central Florida banks. In 2009, Mr.LaRoe opened First Green Bank after being granted the last bank charter in the state of Florida, and that is where his story becomes woven into today's Summit... Michael Patterson, NHA, OTR/L | US Cannabis Michael is a subject matter expert in the global cannabis industry. With 25 years as a healthcare executive and his expertise in the hemp and cannabis industries, Mr. Patterson has been a sought-after authority, addressing audiences at numerous conferences, including the 2019 UBS Global Consumer and Retail Conference, FBI National Academy, CBD East Convention. Taylor Biehl | Capital Alliance Group Taylor Patrick Biehl is the Legislative Programs Director for the Capitol Alliance Group and co-founder of the Medical Marijuana Business Association of Florida. With over a decade of direct legislative experience with major appropriations issues and a concentrated focus on local governance, property taxation, and agency regulation issues, he has proven himself to be a tireless advocate for clients’ interests. Francis Grady | Grady & Associates Francis Grady combines government and private practice experience as an attorney with the Federal Deposit Insurance Corporation in Washington, D.C and as an attorney in private practice. Francis provides bank regulatory, corporate and securities law representation to more than 100 regulated financial institutions across the country in matters involving bank supervision and bank regulatory enforcement actions, BOLI, executive compensation, merger transactions, securities offerings and shareholder relations. Christopher Johnson | Integrated Compliance Solutions, LLC Chris is the Co-Founder and Chief Executive Officer for Integrated Compliance Solutions, LLC. Prior to joining ICS, Chris was responsible for senior leadership functions across the processing and financial services industry. Chris bring 20 years of experience in the financial services and a wealth of knowledge and experience in banking, processing, system design and operations. ABOUT THE SPEAKERS Angela Lucas | Sterling Compliance, LLC As a former bank regulator and seasoned consultant, Angela's knowledge of regulatory compliance, risk management and investment advisory services has established her reputation as a leading resource with the financial institution consulting industry, spanning consumer protection and anti-money laundering statutes, fraud and marijuana banking issues. Joseph Kopko, MS, CSP | HUB International As EVP, Client Services & Business Development, Joe has nearly 20 years of experience proactively managing safety, risk, and employee health. Joe oversees the strategic servicing of clients to overlap their insurance program with the appropriate technology and service strategies that will create a proactive risk management experience. His primary specialty is in developing leadership and management teams to support a sustainable culture of prevention and resiliency. Evan Muffly | HUB International Evan is EVP and Practice Leader for HUB International's Captive Practice. Mr. Muffly is responsible for providing strategic direction, growth and execution of the practice across he HUB organization globally. Evan has worked in multiple facets of the captive insurance industry, including business development, domicile regulation development, feasibility studies, captive formation, administration and ongoing management. Ralf Kaiser | Integrated Compliance Solutions, LLC Ralf has been involved in the investment and financial industries for 30 years with a focus on capital raising, investment management, start-ups and the capital markets. Ralf joined ICS in 2018 and has been actively involved in the capital raising, market development and bank sales strategies for the firm. Mr. Kaiser brings a wealth of knowledge and experience to the firm in investment, financial services, sales & marketing and operations. SUMMIT HOSTS Integrated Compliance Solutions, LLC Integrated Compliance Solutions, LLC (ICS) is one of the leading marijuana banking compliance firms. Providing complete compliance solutions for banks, credit unions, and other financial institutions, ICS is the true SEED TO BANK™ strategy for marijuana financial institutions. ICS has worked with numerous banks and credit unions in many of the legal states to establish MRB banking compliance programs and successfully accept MRB deposits. www.icslv.com | 702.844.8723 | [email protected] Sterling Compliance, LLC Sterling Compliance is a strategic risk management partner to our community bank and credit union clients. With over 80 years of combined experience as bank regulators, bankers and consultants, we bring a balanced perspective in our approach to compliance and credit risk management. Our clients rely on us to help them develop, assess and manage effective regulatory compliance programs, provide credit review services, and stay ahead of the regulatory examination cycles with forward-looking, timely information and guidance on pending or changing regulations, emerging risks and reviews of current practices. Through a combination of strategic planning, transactional reviews and audits, our Navigator newsletter and multiple delivery channels for training, we provide a full suite of services to maximize the efficiency and effectiveness of your compliance function. Sterling has been on the forefront of developing tools and education for banks and credit unions seeking to manage the risk associated with marijuana-related businesses in the current regulatory environment. www.sterlingcompliancellc.com | 412.356.3787 | [email protected] CONTACT THE SPEAKERS T A Y L O R K E N M I C H A E L B I E H L L A R O E P A T T E R S O N Capitol Alliance Group, Inc First Green Bank US Cannabis Pharmaceutical Office: 850.224.1660 [email protected] Research and Development LLC Cell: 352.281.1773 Office: 321.960.9699 [email protected] [email protected] A N G E L A C H R I S T O P H E R J O S E P H L U C A S J O H N S O N K O P K O Sterling Compliance, LLC Integrated Compliance Solutions, LLC HUB International Limited Office: 412.356.3787 Office: 702.844.8723 Office: 412. 992.2838 Cell: 412.855.7740 Cell: 980.229.5978 Cell: 724-.422.0554 [email protected] [email protected] [email protected] E V A N R A L F F R A N C I S M U F F L Y K A I S E R G R A D Y HUB International Limited Integrated Compliance Solutions, LLC Grady & Associates Office: 412. 992.2838 Office: 702-844-8723 Office: 440.356.7255 [email protected] Cell: (780) 938-7722 Cell: 216.308.0095 [email protected] [email protected] THANK YOU! 1 NOTE S The U.S. Cannabis Industry from Illegal to Legal How Did We Get Here? Florida as Our Case Study 2 NOTE S Florida’s Official Source for Responsible Use 3 NOTE S MMBAFL: Who We Are • The Medical Marijuana Business Association of Florida (MMBAFL) was founded in 2014 as a membership organization to: protect and promote a rational and compassionate approach to Florida’s emerging medical marijuana regulatory framework for patients; serve as a responsible business resource for policy makers; identify best practices from other states which have authorized medical cannabis; support and grow business opportunities for the emerging medical marijuana industry. 4 4 NOTE S U.S. Marijuana Law: A Short History The effort to curtail Mexican immigrants prompted the Marijuana Tax Act of 1937 which effectively banned its use and sales. Later it was ruled unconstitutional. It was replaced with the Controlled Substances Act in the 1970’s which established Schedules for ranking substances according to their dangerousness and potential for addiction. Cannabis was placed in the most restrictive category, Schedule I, In 1972, the Schafer Commission declared that marijuana should not be in Schedule I and even doubted its designation as an illicit substance, however President Nixon rejected the findings. Prior to 1937, cannabis had enjoyed a 5000 year history as a therapeutic agent across many cultures. In this context, its blip as an illicit and dangerous drug was dwarfed by its role as a medicine. 5 5 NOTE S State Ballot Initiatives In 1996, California became the first state to approve the use of marijuana for medical purposes, ending its 59 year reign as an illicit substance with no medical value. Following CA, four states (Washington, Oregon, Alaska, Maine) and D.C. passed medical marijuana laws In response to President Raegan’s “War on Drugs”, during which new federal mandatory minimum sentences were introduced, states began legalizing the use of medical marijuana leading to 8 more states passing medical marijuana laws from 2000-2010. On November 6, 2012, Colorado and Washington became the first states to legalize recreational use of cannabis, regulating cannabis in a way similar to alcohol, allowing possession of up to an ounce for adults ages 21 and older.
Load more

Recommended publications
  • The Green Regulatory Arbitrage
    Table of Contents I. EXECUTIVE SUMMARY ...................................................................................................... 1 II. PROHIBITION - HOW CANNABIS BECAME ILLEGAL ..................................................... 4 III. THE LEGAL LANDSCAPE .................................................................................................... 7 A. Federal Law And Its Impact On The Cannabis Industry ..................................................... 7 1. Cannabis Is A Schedule 1 Substance ............................................................................ 7 2. Access To Capital Markets Restricted ......................................................................... 9 3. Banking Services Limited .......................................................................................... 10 4. Tax Burdens .............................................................................................................. 11 5. Interstate And International Commerce Restrictions ................................................. 11 6. Insurance Options Limited ........................................................................................ 12 7. Medical Research And Clinical Trials Stymied .......................................................... 12 8. Professional Services Harder To Find ........................................................................ 13 9. Real Estate Challenges .............................................................................................. 13 B. The States
    [Show full text]
  • Q1 2019 Your Cannabis Investment Resource
    THE CANNIN REPORT | Q1/3 Q1 2019 Your Cannabis investment resource. THE CANNIN REPORT | Q1/3 table of contents 03 | welcome 04 | partner companies 05 | fundamental analysis 65 | cannin investing terms-to-know 67 | cannin cannabis terms-to-know 2 THE CANNIN REPORT | Q1/3 Cannin Report Q1 2019 – Cannabis Cultivators in the USA Welcome to Cannabis Investing in 2019! It’s crazy out there, we know. That’s why we put together our quarterly reports; to help you discern gold from fool’s gold. In the following pages you’ll find helpful terms-to-know for both cannabis and investing, deep analyses of 12 of the largest cannabis companies in the United States, and a piece on the important points on how to grow cannabis so you know what to look for when evaluating cannabis cultivators. Our team of industry experts has made this report easy to read, easy to understand, and easy to digest so that you’ll have the information you need to make the most profitable investments this calendar year. Thanks for purchasing, happy reading, and stay tuned to the next Cannin report (Q2) on the largest publicly traded hemp companies! Stephen Goldman & William Goodin Founders 3 THE CANNIN REPORT | Q1/3 4 THE CANNIN REPORT | Q1/3 55 THE CANNIN REPORT | Q1/3 A Short Explanation on How Cannin Evaluates Cannabis Companies Prior to investing in any stock, it’s important to do your homework. Fundamental analyses and technical analyses are essential to any stock evaluation and should be done with care. Cannin is here to help.
    [Show full text]
  • Bill Analysis and Fiscal Impact Statement
    The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Agriculture BILL: SB 1766 INTRODUCER: Senator Powell SUBJECT: Sale of Hemp-derived Delta-8-tetrahydrocannabinol DATE: March 16, 2021 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Pre-meeting 2. CJ 3. RC I. Summary: SB 1788 creates s. 581.218, F.S., to regulate the sale of hemp-derived delta-8- tetrahydrocannabinol (delta-8-THC) products. It provides definitions for certain terms relating to the sale of delta-8-THC products. The bill specifies that a sale of hemp-derived dela-8-THC products constitutes a delivery sale regardless of whether the person accepting the order for the delivery is located in Florida. A retailer who mails or ships any hemp-derived delta-8-THC products must: Obtain a certification from the consumer who is purchasing the product that he or she is 21 years of age or older; Include as part of the order’s shipping documents, in a clear and conspicuous manner, the following statement: “Hemp-derived Delta-8-Tetrahydrocannabinol Products: Florida law prohibits shipping to individuals under 21 years of age and requires the payment of all applicable taxes”; and Be in compliance with any labeling requirements, pursuant to Department of Agriculture and Consumer Services rule for the state hemp program. The bill outlines specific violations that are misdemeanors of the first degree. The bill is effective July 1, 2021 BILL: SB 1766 Page 2 II.
    [Show full text]
  • As the Industry Develops, Cannabis and CBD Producers Sail Into the Dangerous Shoals of Product Recalls
    As the Industry Develops, Cannabis And CBD Producers Sail Into the Dangerous Shoals of Product Recalls By: Richard M. Blau, Chairman Cannabis Law Group Now that the federal government has legalized hemp and defined lawful cannabidiol (CBD) produced from hemp, the market for CBD products has moved forward with exponential growth. In 2018, approximately $620 million worth of CBD products were sold in the United States. Popular economic advice platforms such as The Motley Fool report projections from economists and industry experts estimating future growth at approximately $24 billion by 2023. Growing CBD revenue from $620 million in 2018 to $23.7 billion by 2023 delivers a compound annual growth rate (CAGR) of 107%. While such statistics reflect a maturing market, so, too , do the arrival of product recalls. Recently, several CBD companies announced voluntary recalls of their products. Summit Labs’ Kore Organic Watermelon CBD Oil On May 12, 2020, Florida-based Summitt Labs, which produces a wide range of hemp-derived cannabidiol (CBD) products, announced a voluntary nationwide recall of its Kore Organic watermelon tincture after the Florida Department of Agriculture and Consumer Affairs conducted a test on a random sample and found high levels of lead. When ingested, lead can cause various symptoms such as pain, nausea and kidney damage; in prolonged exposure situations, lead poisoning has been shown to contribute to degraded brain functions. Summit Labs conducted its own test through an accredited, independent lab that found the lead levels in an acceptable range under state law. But, because the Florida officials found excess lead levels in the sample they tested, Summitt quickly moved to withdraw the product from retailers, who have been notified by phone and email.
    [Show full text]
  • Liberty Health Sciences Inc. Management's Discussion
    LIBERTY HEALTH SCIENCES INC. MANAGEMENT’S DISCUSSION & ANALYSIS This management discussion and analysis (“MD&A”) of the financial condition and results of operations of Liberty Health Sciences Inc., (the “Company” or “Liberty”), is for the three and six month period ended August 31, 2019, and 2018. It is supplemental to, and should be read in conjunction with the Company’s unaudited interim condensed consolidated financial statements and the accompanying notes for the three and six month period ended August 31, 2019, and 2018 (the “Q2 2020, and Q2 2019 Financials”) as well as the audited consolidated financial statements for the year ended February 28, 2019. The Company’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). This MD&A has been prepared by reference to the MD&A disclosure requirements established under National Instrument 51-102 “Continuous Disclosure Obligations” (“NI 51-102”) of the Canadian Securities Administrators. Additional information regarding Liberty Health Sciences Inc. is available on our website at www.libertyhealthsciences.com or through the SEDAR website at www.sedar.com. In this MD&A, reference is made to gross profit before biological asset adjustments, gross margin before biological asset adjustments and adjusted earnings before interest, tax, depreciation and amortization (“EBITDA”), which are not measures of financial performance under IFRS and may not be comparable to similarly titled measures used by other companies. The Company calculates each as follows: • Gross profit before biological asset adjustments is equal to gross profit less the non-cash change in the fair value on harvest and less the non-cash change in the fair value on cost of goods sold, if any.
    [Show full text]
  • CBD) Products Rich in CBD
    924 17th Ave SE Apt. 303 Minneapolis, Minnesota 55414 Sensible policies, safer communities. Representative Rob EcklunD, Chair Labor, InDustry, Veterans, anD Military Affairs Finance & Policy 409 State Office Building St. Paul, MN 55155 Re: House File 600 (Winkler) Cannabis Legalization Dear Chair Ecklund and Members of the Committee, I write toDay on behalf of Sensible Change Minnesota, in support of House File 600. We first want to thank Representative Winkler for his collaborative anD thoughtful approach in Developing this legislation. As an organization, we have done substantial work on improving Minnesota’s medical cannabis program. Our team has worked for the addition of intractable pain, post-traumatic stress disorder, autism, Alzheimer’s disease, and chronic pain as qualifying conditions, and oral dissolvable medical cannabis proDucts. We have also repeatedly engaged the legislature in an attempt to pass patient- centric legislation that will make medical cannabis more affordable and accessible for some of Minnesota’s sickest patients. We know: • the cost of meDical cannabis is extremely high in Minnesota, and insurance Does not cover the cost of this effective medicine for patients who are often disabled and limited in their ability to work; • Minnesota has a low percentage of its population in its meDical cannabis program compareD to states with more effective programs; • patients face limited options and access due to the limit of two medical cannabis manufacturers; anD • Minnesota’s two meDical cannabis companies have struggleD to turn a profit. We also know that cannabis prohibition was founDeD in racism anD irrational policy making, anD that the lasting effects of this faileD policy have disproportionately damageD communities of color.
    [Show full text]
  • Bill Analysis and Fiscal Impact Statement
    The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Rules BILL: CS/CS/CS/SB 1876 INTRODUCER: Rules Committee; Innovation, Industry, and Technology Committee; Agriculture Committee; and Senator Montford SUBJECT: State Hemp Program DATE: March 3, 2020 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Fav/CS 2. Oxamendi Imhof IT Fav/CS 3. Becker Phelps RC Fav/CS Please see Section IX. for Additional Information: COMMITTEE SUBSTITUTE - Substantial Changes I. Summary: CS/CS/CS/SB 1876 makes changes to the state hemp program. Specifically, the bill: Includes hemp extract in the definition of “food” in the Florida Food Safety Act; Requires persons who operate minor food outlets (which sell only commercially prepackaged food that is not potentially hazardous, or not time or temperature controlled for safety, if the shelf space for those items does not exceed 12 total linear feet) that sell hemp extract to obtain a food permit from the Department of Agriculture and Consumer Services (department); Excludes a substance or compound that is intended for ingestion which contains less than trace amounts of cannabidiol and includes a substance or compound that is intended for inhalation in the definition of “hemp extract;” Exempts synthetic cannabidiol (CBD) oil and seeds and seed-derived ingredients that are generally recognized as safe by the United States Food and Drug Administration from the definition of “hemp extract;” Provides that, if the plan submitted by the department to the Secretary of the U.S.
    [Show full text]
  • 2020 Minnesota Medical Cannabis Pricing Report
    Minnesota Medical Cannabis Pricing and Patient Experience Report Produced and published by Sensible Change Minnesota www.changemn.org Minnesota Medical Cannabis Pricing and Patient Experience Report Sensible Change Minnesota About Sensible Change Minnesota Sensible Change Minnesota grew out of our sister organization, Sensible Minnesota, to allow for more flexibility to advocate for sensible drug policy reforms unburdened by its 501(c)3 lobbying restrictions. Our team is responsible for many of the expansions of Minnesota’s medical cannabis program, including: • Intractable Pain, effective August 2016 • Post-Traumatic Stress Disorder (PTSD), effective August 2017 • Autism Spectrum Disorder, effective August 2018 • Alzheimer’s Disease, effective August 2019 • Reducing the qualifications for a patient to have a caregiver in the program, effective August 2019 (HF766, Section 6) • Chronic Pain, effective August 2020 • Oral dissolvable products, effective August 2020 15,994 of Minnesota’s 18,249 registered patients (87.6%) qualify for the program because of a condition that Sensible Minnesota successfully petitioned MN’s Health Commissioner to add. Sensible Change Minnesota’s Board of Directors is comprised of grassroots activists, patients, caregivers, legal professionals, and union organizers. We amplify the voices of patients and consumers at the legislature. Questions on this report can be referred to Maren Schroeder, Policy Director, [email protected]. Page 2 of 18 Minnesota Medical Cannabis Pricing and Patient Experience Report Sensible Change Minnesota Key Findings ● 86 percent of surveyed registered medical cannabis patients reported price as the primary treatment barrier; 76 percent reported no access to raw cannabis plant material as a treatment barrier. ● Inhalation oil cartridges are, on average, 52 percent more expensive than raw cannabis plant material on a per mg of THC basis; capsules are 75 percent more expensive than raw cannabis plant material on a per mg of THC basis.
    [Show full text]
  • Trulieve: the Production of Medicinal Marijuana in Florida©
    Trulieve: the production of medicinal marijuana in Florida© G. Hackneya George Hackney, Inc., Hackney Nursery, 3690 Juniper Creek Road, Quincy, Florida 32351, USA. INTRODUCTION This paper reports on the process of starting the first legal medical marijuana production and dispenser facility in northwest Florida—Trulieve. Trulieve is now a Florida licensed medical Cannabis provider, http://trulieve.com/about. The product produced is low THC-Cannabis, which means a patient will not get “high” from the low dosage. The goal is for medical pain relief, as well as the control of seizures—some epileptic children suffer from as many as 100 seizures per day. The plants are produced at an unknown location in Quincy, Florida—for an extraction process to infuse into medical devices via oral syringe, capsule, tincture, or vaporizer. In Tallahassee, the dispensary sells products using Cannabis extract—from capsules to vaporizer use (Steven Jiwanmall, 29 Sept 2016. Insiders: A look at medical Cannabis in Florida, http://www.wtxl.com/insiders/insiders-a-look-at-medical- cannabis-in-florida/article_edddc022-89ad-11e6-a4ea-03bc56885560.html). COMPASSIONATE CARE ACT • Spring 2014: medical marijuana amendment is placed on the November ballot. • May 2014: legislation passes “Compassionate Care” Act. The Florida legislature is Republican controlled. FOR A NURSERY TO QUALIFY • 30 year license by Florida Department of Agriculture. • License has to be at 400,000 plant production level. • Product must be available by 1 Jan. 2015. LEGISLATIVE PROCESS • Fall 2014: (1) Rule making sessions begin/New Venture; (2) legal challenges to the rules; (3) lottery system is thrown out. • February 2015: Special rule making body appointed by Florida Department of Health.
    [Show full text]
  • BLUMA WELLNESS INC. CSE FORM 2A LISTING STATEMENT June 11
    BLUMA WELLNESS INC. CSE FORM 2A LISTING STATEMENT June 11, 2020 TOR_LAW\ 10222355\17 Bluma Wellness Inc. (“Bluma”) derives a substantial portion of its consolidated revenues from the medical cannabis industry in the State of Florida, where local state laws permit such industry but is illegal under United States federal law. Bluma is directly engaged in the manufacture, possession, use, sale and distribution of medical cannabis in the State of Florida. Third party service providers could suspend or withdraw services and regulatory bodies couple impose certain restrictions on Bluma as a result of Bluma’s operating in an industry that is illegal under U.S. federal law. The United States federal government regulates drugs through the Controlled Substances Act (the “CSA”) (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I controlled substance. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The CSA explicitly prohibits the manufacturing, distribution, selling and possession of cannabis and cannabis derived products as a consequence of its Schedule I classification. The United States Food and Drug Administration has not approved marijuana as a safe and effective drug for any indication. In the United States, cannabis is largely regulated at the state level. State laws that permit and regulate the production, distribution and use of cannabis for medical or recreational purposes are in direct conflict with the federal CSA, which makes cannabis use and possession federally illegal.
    [Show full text]
  • Trulieve: the Production of Medicinal Marijuana in Florida©
    1 Trulieve: The Production of Medicinal Marijuana in Florida© George Hackney George Hackney, Inc. - Hackney Nursery, 3690 Juniper Creek Road, Quincy, Florida 32351 [email protected] INTRODUCITION This paper reports on the process of starting the first legal medical marijuana production and dispenser facility in Northwest Florida - Trulieve. Trulieve is now a Florida licensed medical cannabis provider http://trulieve.com/about . The product produced is low THC-cannabis, which means a patient will not get “high” from the low dosage. The goal is for medical pain relief, as well as the control of seizures – some epileptic children suffer from as many as 100 seizures per day. The plants are produced at an unknown location in Quincy, Florida - for an extraction process to infuse into medical devices via oral syringe, capsule, tincture or vaporizer. In Tallahassee, the dispensary sells products using Cannabis extract – from capsules to vaporizer use (Steven Jiwanmall, 29 Sept 2016. Insiders: A look at medical Cannabis in Florida, http://www.wtxl.com/insiders/insiders-a-look-at-medical-cannabis-in-florida/article_edddc022- 89ad-11e6-a4ea-03bc56885560.html ) COMPASSIONATE CARE ACT Spring 2014 - Medical marijuana amendment is placed on the November Ballot. 2 May 2014 - Legislation Passes “Compassionate Care” Act. The Florida legislature is Republican controlled. FOR A NURSERY TO QUALIFY 30 year license by Florida Department of Agriculture. License has to be at 400,000 plant production level. Product must be available by 1 January 2015. LEGISLATIVE PROCESS Fall 2014 – 1) Rule making sessions begin / New Venture; 2) legal challenges to the rules; 3) lottery system is thrown out.
    [Show full text]
  • City of Sanibel Ordinance 17-002 an Ordinance of The
    CITY OF SANIBEL ORDINANCE 17-002 AN ORDINANCE OF THE CITY OF SANIBEL, ESTABLISHING A TEMPORARY MORATORIUM ON CANNABIS DISPENSING BUSINESSES AS FURTHER DEFINED HEREIN; PROVIDING FOR GEOGRAPHIC AREA COVERED; PROVIDING FOR PENALTIES; PROVIDING A SAVINGS CLAUSE; PROVIDING FOR SEVERABILITY; PROVIDING FOR CODIFICATION; AND PROVIDING FORAN EFFECTIVE DATE. WHEREAS, in 2014 the Florida Legislature enacted a law legalizing low-THC medical cannabis in Florida; and WHEREAS, in 2016 the Florida Legislature expanded the law to legalize medical cannabis in Florida; and WHEREAS, in November, 2016 the Florida electorate passed a Constitutional Amendment which legalized the use of medical marijuana under state law in accordance with the provisions set forth in such Constitutional Amendment; and WHEREAS, a comprehensive state licensing and regulatory framework for the cultivation, processing, and dispensing of cannabis now exists under state statutory law, however the licensing and re1,>ulatory scheme to implement the 2016 Constitutional Amendment are currently being developed by tbe state; and WHEREAS, the current state licensing and regulatory framework directs that tbe criteria for the number and location of, and otber permitting requirements that do not conflict with state law or department rule for, dispensing facilities of cannabis businesses may be determined by local ordinance; and WHEREAS, cannabis businesses licensed pursuant to the current state law have begun cultivating cannabis for processing and dispensing; and 1 Ord 17-002 WHEREAS, the dispensing
    [Show full text]